Friday, August 14, 2020
News
NEWS HOME
»
PRESS RELEASES

Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus
  SocialTwist Tell-a-Friend  
   


Date: 10-07-2020 12:15PM
Source: Mundipharma
Category: General, Science & Research, Healthcare & Biotechnology, Medical Devices, Retailers
Location: Singapore

Business Wire India

Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease.

Testing has demonstrated BETADINE’s® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I).

The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020.

“These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, CEO Mundipharma.

“It also provides the medical community as well as consumers with a science-based assurance that they are using a product that is a proven defence against COVID-19,” he added.

The study conducted at Duke-NUS is complemented by Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that also demonstrated strong in-vitro virucidal activity, with the tested product BETADINE® Gargle and Mouthwash (1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds. The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.

Previously, BETADINE® antiseptic products containing povidone iodine (PVP-I) have been proven effective in vitro against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is highly effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

About BETADINE®

The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® povidone iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.

®: BETADINE is a registered trademark of Mundipharma

For more information please visit: www.mundipharma.com.sg.



CONTACTS :

For further information please contact:
Email: media@mundipharma.com.sg

More Press Releases

Bajaj Finserv Doctor Loan - Here’s How Medical Practitioners Can Benefit from Its Notable Features

Mindteck Reports Financial Results for Q1 2020-21

Flex Releases 2020 Sustainability Report

FSS Launches Embark to Digitally Strengthen India’s MSME Segment

High School Internships Made Possible, by Industry Pioneer Alacrous

Hyundai Mobility Membership India’s First Smart Ownership and Lifestyle Experience

NoPaperForms Marks Three Years with ESOP Announcement Worth over USD2 Million

Kent RO Salutes the Real Heroes

Lattice Sentry Solutions Stack and SupplyGuard Service Deliver End-to-End Supply Chain Protection with Dynamic Trust

Lenovo Delivers Outstanding Q1 Performance and Strong Growth, Overcoming Challenging Global Environment

Federal Bank Chooses Fiserv to Support Launch of Their First Independent Credit Card

Velodyne Lidar Powering Intelligent Traffic Management in Nevada

Premier Philippines Airport Enhances Passenger Throughput and Experience with Smiths Detection

Win a Tablet with WorldRemit’s Back to School Competition!

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives

Moody’s Analytics Three-Peats in Two Categories at Risk Technology Awards

Visa Selects Payswiff as Winner of Visa Everywhere Initiative 2020 in India

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Maharashtra prisons COVID count stands a...
Defence Minister Rajnath Singh launches ...
RTI disposal rate remains unaffected by ...
India can emerge as major player in glob...
ABVP seeks SAU re-conduct entrance test ...
1 killed, 5 injured in Mumbai building c...
More...    
 
 Top Stories
Trump stokes Kamala Harris 'birther... 
Italy PM defends government's handl... 
Pak's Independence Day is Black Day... 
Despite COVID-19 disruptions, Ace G... 
HARMAN launches AccuAlertMe - An en... 
Cyril Amarchand Mangaldas advises A... 
Will talk to CM to allocate relief ... 
WHO in conversation with Russia for...